The 2025 Biologics Contract Manufacturing Report
The 2025 edition of our annual report offers new analysis of the global rebound in biologics outsourcing following a year of macroeconomic headwinds and market contraction.
Download this report and get insights into the CDMO landscape, covering manufacturing demand, regional investment, and therapeutic innovation across biologic therapies, including protein-based therapies, non-protein vaccines, and advanced therapies.
Preview Our Findings
- Resurgent market growth: The global biologics CDMO market grew 11% in 2024, reaching $20.7B, driven by rising demand for complex manufacturing solutions. Advanced therapies were the fastest-growing segment, expanding 37% year-over-year to $3.7B and now representing 18% of total CDMO value. Protein-based biologics remained dominant, accounting for 66% of the market, supported by continued momentum in monoclonal antibodies and GLP-1 programs.
- Consolidation at the top: In 2024, the top eight CDMOs captured 51 percent of total market revenue, generating 10.6 billion dollars out of the 20.7 billion total. Large and mid-sized providers now control 80 percent of market value, reflecting strong sponsor preference for scale, integrated capabilities, and regulatory maturity.
- Regional strategy shifts: While North America leads with commercial-scale infrastructure and regulatory depth, Europe stands out for process development and early-stage innovation, while Asia accelerates global capacity expansion. Each region plays a distinct, strategic role in shaping the future of biologics manufacturing.
- Changing sponsor expectations: Biopharma companies are increasingly seeking CDMOs with early-stage integration, digital quality systems, and flexible platforms capable of supporting complex, high-value therapies.
The 2025 Biologics Contract Manufacturing Report
The 2025 edition of our annual report offers new analysis of the global rebound in biologics outsourcing following a year of macroeconomic headwinds and market contraction.
Access insight into the CDMO landscape, covering manufacturing demand, regional investment, and therapeutic innovation across biologic therapies, including protein-based therapies, non-protein vaccines, and advanced therapies.
Preview Our Findings
- Resurgent market growth: The global biologics CDMO market grew 11% in 2024, reaching $20.7B, driven by rising demand for complex manufacturing solutions. Advanced therapies were the fastest-growing segment, expanding 37% year-over-year to $3.7B and now representing 18% of total CDMO value. Protein-based biologics remained dominant, accounting for 66% of the market, supported by continued momentum in monoclonal antibodies and GLP-1 programs.
- Consolidation at the top: In 2024, the top eight CDMOs captured 51 percent of total market revenue, generating 10.6 billion dollars out of the 20.7 billion total. Large and mid-sized providers now control 80 percent of market value, reflecting strong sponsor preference for scale, integrated capabilities, and regulatory maturity.
- Regional strategy shifts: While North America leads with commercial-scale infrastructure and regulatory depth, Europe stands out for process development and early-stage innovation, while Asia accelerates global capacity expansion. Each region plays a distinct, strategic role in shaping the future of biologics manufacturing.
- Changing sponsor expectations: Biopharma companies are increasingly seeking CDMOs with early-stage integration, digital quality systems, and flexible platforms capable of supporting complex, high-value therapies.
Subscribe to our newsletter for the latest news, events, and thought leadership